PharmaTher Holdings Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fabio Chianelli
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Jan 8, 2021
- Website
- pharmather.com
- Similar Companies
- Business
- PharmaTher Holdings Ltd. is a clinical-stage specialty pharmaceutical company focused on the research, development, and commercialization of ketamine-based therapies for mental health, neurological, pain, and orphan drug indications. Founded in 2019 and headquartered in Toronto, Ontario, Canada, the company operates primarily in North America with pursuits of international partnerships. Its core products and services encompass KETARx (racemic ketamine) for anesthesia, sedation, depression, pain, and neurological disorders; patented long-acting injectable ketamine (KET-100) via an exclusive evaluation and option-to-license agreement with Oakwood Laboratories; novel delivery systems including microneedle patches and wearable pumps; and previously KETABET, alongside an Abbreviated New Drug Application (ANDA #217858) for ketamine hydrochloride injection. In recent developments, PharmaTher closed the sale of its Ketamine ANDA to a leading global sterile-injectables company in December 2025, securing an upfront cash payment, potential milestone payments exceeding US$25 million based on sales thresholds, and seven-year profit-sharing to support commercialization without dilution; entered the exclusive long-acting ketamine agreement with Oakwood Laboratories in November 2025; received US patent protection for ketamine in amyotrophic lateral sclerosis (ALS); advanced FDA interactions including an extended review for ketamine approval targeting August 2025 and engagement on National Priority Voucher opportunities; and launched KetaVault, a portal to accelerate ketamine research.
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
PharmaTher CEO Publishes Letter to Shareholders
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease